In one study, the company’s drug eased the agitation for Alzheimer’s patients. In a different study, there wasn’t a ...

In a report released yesterday, Myles Minter from William Blair reiterated a Buy rating on Axsome Therapeutics (AXSM – Research Report). The ...

Axsome Therapeutics said it would submit its Alzheimer’s disease treatment for FDA approval despite mixed results from two ...

Shares of Axsome Therapeutics (AXSM) fell over 11% in Monday morning trade after it posted mixed results of its Alzheimer’s ...

Needham & Company LLC reiterated their buy rating on shares of Axsome Therapeutics (NASDAQ:AXSM – Free Report) in a research ...

Axsome Therapeutics shows strong revenue growth with promising pipeline drugs for migraine, fibromyalgia, and narcolepsy.

On Monday, Axsome Therapeutics, Inc. (NASDAQ:AXSM) released data from ACCORD-2, ADVANCE-2, and long-term safety trials AXS-05 ...

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $139.75, along ...

With two earlier trials meeting their primary endpoints, Axsome claimed it has the data to support a filing for FDA approval ...

Axsome Therapeutics (AXSM) stock fell 12% Monday after the company reported mixed Phase 3 results for its drug AXS-05 in the ...

In a report released yesterday, Vikram Purohit from Morgan Stanley maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report), ...

Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer’s Disease ...